Molecular Partners (OTCMKTS:MLLCF – Get Free Report) will likely be posting its results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.4008) per share for the quarter.
Molecular Partners Price Performance
Shares of OTCMKTS MLLCF opened at $4.01 on Wednesday. The firm’s 50-day moving average price is $3.97 and its two-hundred day moving average price is $3.33. Molecular Partners has a 52-week low of $2.25 and a 52-week high of $4.85.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland. The company discovers and develops protein therapeutics based on its proprietary DARPin platform, which uses engineered ankyrin repeat proteins to create targeted and potentially multi-specific medicines.
Molecular Partners’ research focuses primarily on oncology, immuno-oncology and other serious diseases in which precisely targeted protein therapies may offer therapeutic advantages.
Read More
- Five stocks we like better than Molecular Partners
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
